Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9927662 | 0.93 | CYP2C9 (0.38) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL9927541 | 0.86 | CYP2C9 (0.39) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL9927693 | 0.84 | CYP2C9 (0.36) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL15340301 | 0.82 | CYP2C9 (0.37) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL14235341 | 0.81 | OPRL1 (0.43) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL12716105 | 0.81 | OPRL1 (0.43) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL9927629 | 0.81 | ALOX5 (0.43) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL9927550 | 0.81 | OPRL1 (0.34) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL9927661 | 0.80 | CYP2C9 (0.37) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL2606306 | 0.79 | CYP2C9 (0.38) | CYP2C9ALDH1A1LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468740-B1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY DEVICES | JNC CORP (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9663716-B2 | Tetrahydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9663716-B2 | Tetrahydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2468740-A1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY ELEMENTS | JNC Corporation (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| WO-2011021534-A1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY ELEMENTS | チッソ株式会社 (JP) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, CCND1, CCND2 | CYP2C9 733/4885ALDH1A1 686/4885LMNA 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.